دورية أكاديمية
In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies.
| العنوان: | In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies. |
|---|---|
| المؤلفون: | Li D; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA., Edwards RJ; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA., Manne K; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA., Martinez DR; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA., Schäfer A; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA., Alam SM; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA., Wiehe K; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA., Lu X; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA., Parks R; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA., Sutherland LL; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA., Oguin TH 3rd; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA., McDanal C; Department of Surgery, Duke University, Durham, NC 27710, USA., Perez LG; Department of Surgery, Duke University, Durham, NC 27710, USA., Mansouri K; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA., Gobeil SMC; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA., Janowska K; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA., Stalls V; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA., Kopp M; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA., Cai F; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA., Lee E; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA., Foulger A; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA., Hernandez GE; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA., Sanzone A; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA., Tilahun K; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA., Jiang C; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA., Tse LV; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA., Bock KW; Infectious Disease Pathogenesis Section, Comparative Medicine Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA., Minai M; Infectious Disease Pathogenesis Section, Comparative Medicine Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA., Nagata BM; Infectious Disease Pathogenesis Section, Comparative Medicine Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA., Cronin K; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA., Gee-Lai V; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA., Deyton M; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA., Barr M; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA., Von Holle T; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA., Macintyre AN; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA., Stover E; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA., Feldman J; Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA., Hauser BM; Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA., Caradonna TM; Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA., Scobey TD; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA., Rountree W; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA., Wang Y; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA., Moody MA; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA; Department of Pediatrics, Duke University School of Medicine, Durham, NC 27710, USA., Cain DW; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA., DeMarco CT; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA., Denny TN; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA., Woods CW; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA; Center for Applied Genomics and Precision Medicine, Duke University Medical Center, Durham, NC 27710, USA., Petzold EW; Center for Applied Genomics and Precision Medicine, Duke University Medical Center, Durham, NC 27710, USA., Schmidt AG; Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA; Department of Microbiology, Harvard Medical School, Boston, MA 02115, USA., Teng IT; Vaccine Research Center, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, MD 20892, USA., Zhou T; Vaccine Research Center, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, MD 20892, USA., Kwong PD; Vaccine Research Center, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, MD 20892, USA; Department of Biochemistry and Molecular Biophysics, Columbia University, New York, NY 10032, USA., Mascola JR; Vaccine Research Center, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, MD 20892, USA., Graham BS; Vaccine Research Center, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, MD 20892, USA., Moore IN; Infectious Disease Pathogenesis Section, Comparative Medicine Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA., Seder R; Vaccine Research Center, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, MD 20892, USA., Andersen H; BIOQUAL, Rockville, MD 20850, USA., Lewis MG; BIOQUAL, Rockville, MD 20850, USA., Montefiori DC; Department of Surgery, Duke University, Durham, NC 27710, USA., Sempowski GD; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA., Baric RS; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA., Acharya P; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA; Department of Surgery, Duke University, Durham, NC 27710, USA., Haynes BF; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA; Department of Immunology, Duke University School of Medicine, Durham, NC 27710, USA. Electronic address: barton.haynes@duke.edu., Saunders KO; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA; Department of Surgery, Duke University, Durham, NC 27710, USA; Department of Immunology, Duke University School of Medicine, Durham, NC 27710, USA; Department of Molecular Genetics and Microbiology, Duke University School of Medicine, Durham, NC 27710, USA. Electronic address: kevin.saunders@duke.edu. |
| المصدر: | Cell [Cell] 2021 Aug 05; Vol. 184 (16), pp. 4203-4219.e32. Date of Electronic Publication: 2021 Jun 18. |
| نوع المنشور: | Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Cell Press Country of Publication: United States NLM ID: 0413066 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-4172 (Electronic) Linking ISSN: 00928674 NLM ISO Abbreviation: Cell Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Cambridge, Ma : Cell Press Original Publication: Cambridge, MIT Press. |
| مواضيع طبية MeSH: | Antibodies, Neutralizing/*immunology , SARS-CoV-2/*physiology , Spike Glycoprotein, Coronavirus/*immunology, Animals ; Antibodies, Viral/immunology ; Bronchoalveolar Lavage Fluid/chemistry ; COVID-19/pathology ; COVID-19/virology ; Cytokines/metabolism ; Female ; Haplorhini ; Humans ; Lung/pathology ; Lung/virology ; Male ; Mice ; Mice, Inbred BALB C ; Protein Domains ; Receptors, IgG/metabolism ; SARS-CoV-2/isolation & purification ; Spike Glycoprotein, Coronavirus/chemistry ; Viral Load ; Virus Replication |
| مستخلص: | SARS-CoV-2-neutralizing antibodies (NAbs) protect against COVID-19. A concern regarding SARS-CoV-2 antibodies is whether they mediate disease enhancement. Here, we isolated NAbs against the receptor-binding domain (RBD) or the N-terminal domain (NTD) of SARS-CoV-2 spike from individuals with acute or convalescent SARS-CoV-2 or a history of SARS-CoV infection. Cryo-electron microscopy of RBD and NTD antibodies demonstrated function-specific modes of binding. Select RBD NAbs also demonstrated Fc receptor-γ (FcγR)-mediated enhancement of virus infection in vitro, while five non-neutralizing NTD antibodies mediated FcγR-independent in vitro infection enhancement. However, both types of infection-enhancing antibodies protected from SARS-CoV-2 replication in monkeys and mice. Three of 46 monkeys infused with enhancing antibodies had higher lung inflammation scores compared to controls. One monkey had alveolar edema and elevated bronchoalveolar lavage inflammatory cytokines. Thus, while in vitro antibody-enhanced infection does not necessarily herald enhanced infection in vivo, increased lung inflammation can rarely occur in SARS-CoV-2 antibody-infused macaques. Competing Interests: Declaration of interests B.F.H., G.D.S., K.O.S., R.P., D.L., P.A., and X.L. have applied for patents concerning SARS-CoV-2 Abs that are related to this work. All other authors declare no conflict of interest. (Copyright © 2021 Elsevier Inc. All rights reserved.) |
| References: | Nat Struct Mol Biol. 2021 Feb;28(2):128-131. (PMID: 33402708) Cell. 2020 Aug 20;182(4):812-827.e19. (PMID: 32697968) Science. 2020 Aug 21;369(6506):1014-1018. (PMID: 32540904) N Engl J Med. 2021 Feb 4;384(5):403-416. (PMID: 33378609) Cell. 2020 Jun 25;181(7):1458-1463. (PMID: 32492407) Science. 2020 Aug 7;369(6504):643-650. (PMID: 32540902) J Virol Methods. 2009 Jun;158(1-2):171-9. (PMID: 19428587) J Mol Biol. 2009 May 15;388(4):815-23. (PMID: 19324051) Science. 2020 Aug 21;369(6506):1010-1014. (PMID: 32540901) Proc Natl Acad Sci U S A. 1996 Oct 15;93(21):11382-8. (PMID: 8876144) Nature. 2020 Aug;584(7821):437-442. (PMID: 32555388) Science. 2020 Mar 13;367(6483):1260-1263. (PMID: 32075877) Lancet Respir Med. 2020 Jul;8(7):687-695. (PMID: 32386571) Hong Kong Med J. 2016 Jun;22(3 Suppl 4):25-31. (PMID: 27390007) Sci Transl Med. 2020 Nov 4;12(568):. (PMID: 33077678) Nature. 2020 Aug;584(7819):120-124. (PMID: 32454512) Methods Mol Biol. 2015;1282:89-98. (PMID: 25720474) Cell. 2020 Nov 12;183(4):1070-1085.e12. (PMID: 33031744) Nat Med. 2020 Sep;26(9):1422-1427. (PMID: 32651581) Cell. 2020 Jul 9;182(1):73-84.e16. (PMID: 32425270) Nature. 2020 Jul;583(7815):290-295. (PMID: 32422645) Proc Natl Acad Sci U S A. 2011 Aug 23;108(34):14216-21. (PMID: 21825125) Methods Enzymol. 2016;579:125-57. (PMID: 27572726) Vaccine. 2007 Jan 8;25(4):729-40. (PMID: 17049691) Front Immunol. 2014 Apr 22;5:170. (PMID: 24795717) J Comput Chem. 2004 Oct;25(13):1605-12. (PMID: 15264254) Nature. 2008 May 29;453(7195):667-71. (PMID: 18449194) N Engl J Med. 2020 Nov 12;383(20):1920-1931. (PMID: 32663912) Nat Methods. 2017 Mar;14(3):290-296. (PMID: 28165473) J Infect Dis. 2014 May 1;209(9):1331-42. (PMID: 24065148) Nat Microbiol. 2020 Oct;5(10):1185-1191. (PMID: 32908214) J Virol. 2009 Aug;83(15):7397-410. (PMID: 19458010) Sci Transl Med. 2017 Jun 28;9(396):. (PMID: 28659436) Cell. 2021 Jan 21;184(2):476-488.e11. (PMID: 33412089) Science. 2020 Aug 7;369(6504):650-655. (PMID: 32571838) Curr Protoc Microbiol. 2015 May 01;37:15E.2.1-9. (PMID: 26344219) Nature. 2020 Aug;584(7821):353-363. (PMID: 32659783) Nature. 2020 Aug;584(7821):450-456. (PMID: 32698192) J Mol Biol. 2012 Jan 13;415(2):406-18. (PMID: 22100448) Cell. 2020 Apr 16;181(2):281-292.e6. (PMID: 32155444) Cell. 2020 Aug 6;182(3):744-753.e4. (PMID: 32553273) Science. 2020 Oct 23;370(6515):. (PMID: 32972995) J Infect Dis. 2007 Nov 15;196 Suppl 2:S347-56. (PMID: 17940970) Biochem Biophys Res Commun. 2014 Aug 22;451(2):208-14. (PMID: 25073113) Science. 2020 Aug 7;369(6504):731-736. (PMID: 32540900) Cell. 2015 Jun 4;161(6):1280-92. (PMID: 26004070) Science. 2020 Sep 18;369(6510):1501-1505. (PMID: 32703906) Cell. 2020 Jul 23;182(2):429-446.e14. (PMID: 32526206) Virol J. 2014 May 06;11:82. (PMID: 24885320) Virus Res. 2005 Jan;107(1):93-101. (PMID: 15567038) Cell. 2020 May 28;181(5):1004-1015.e15. (PMID: 32375025) Nature. 2020 May;581(7809):465-469. (PMID: 32235945) Acta Crystallogr D Struct Biol. 2018 Jun 1;74(Pt 6):531-544. (PMID: 29872004) Nat Struct Mol Biol. 2020 Sep;27(9):846-854. (PMID: 32661423) Nature. 2020 Aug;584(7819):115-119. (PMID: 32454513) MAbs. 2017 Apr;9(3):393-403. (PMID: 28102754) Science. 2020 Aug 21;369(6506):956-963. (PMID: 32540903) Science. 2020 Oct 23;370(6515):. (PMID: 32972996) Science. 2020 Nov 27;370(6520):1110-1115. (PMID: 33037066) Proc Natl Acad Sci U S A. 2016 Mar 15;113(11):3048-53. (PMID: 26976607) Science. 2020 Jun 12;368(6496):1274-1278. (PMID: 32404477) Acta Crystallogr D Biol Crystallogr. 2010 Apr;66(Pt 4):486-501. (PMID: 20383002) Nat Struct Mol Biol. 2020 Oct;27(10):950-958. (PMID: 32737466) J Virol Methods. 2004 Sep 1;120(1):87-96. (PMID: 15234813) Nature. 2020 Aug;584(7821):443-449. (PMID: 32668443) Clin Vaccine Immunol. 2010 Dec;17(12):1829-35. (PMID: 20876821) Acta Crystallogr D Biol Crystallogr. 2004 Dec;60(Pt 12 Pt 1):2126-32. (PMID: 15572765) Science. 2020 May 29;368(6494):1012-1015. (PMID: 32303590) J Exp Med. 2021 Mar 1;218(3):. (PMID: 33211088) Acta Crystallogr D Struct Biol. 2019 Oct 1;75(Pt 10):861-877. (PMID: 31588918) Nat Rev Immunol. 2020 Jun;20(6):339-341. (PMID: 32317716) J Virol. 2011 Oct;85(20):10582-97. (PMID: 21775467) Nature. 2020 Oct;586(7830):560-566. (PMID: 32854108) Nat Struct Mol Biol. 2020 Oct;27(10):925-933. (PMID: 32699321) Nat Rev Immunol. 2020 Oct;20(10):633-643. (PMID: 32782358) Cell Rep. 2020 Oct 27;33(4):108322. (PMID: 33091382) Science. 2020 May 29;368(6494):945-946. (PMID: 32385100) Front Immunol. 2019 Jun 07;10:1296. (PMID: 31231397) MAbs. 2017 Jul;9(5):767-773. (PMID: 28463043) Acta Crystallogr D Struct Biol. 2018 Jun 1;74(Pt 6):519-530. (PMID: 29872003) ACS Infect Dis. 2016 May 13;2(5):361-76. (PMID: 27627203) Dis Model Mech. 2020 Sep 1;13(9):. (PMID: 32887790) Science. 2020 Aug 14;369(6505):806-811. (PMID: 32434945) J Biosci Bioeng. 2011 Apr;111(4):391-6. (PMID: 21215693) Nature. 2021 Feb;590(7847):635-641. (PMID: 33429418) J Struct Biol. 2005 Jul;151(1):41-60. (PMID: 15890530) Nat Methods. 2017 Apr;14(4):331-332. (PMID: 28250466) N Engl J Med. 2020 Dec 31;383(27):2603-2615. (PMID: 33301246) Protein Sci. 2018 Jan;27(1):14-25. (PMID: 28710774) Nature. 2013 Apr 25;496(7446):469-76. (PMID: 23552890) Mol Immunol. 2008 May;45(10):2752-63. (PMID: 18353438) J Virol. 2020 Feb 14;94(5):. (PMID: 31826992) |
| معلومات مُعتمدة: | F32 AI152296 United States AI NIAID NIH HHS; T32 AI007151 United States AI NIAID NIH HHS; R01 AI157155 United States AI NIAID NIH HHS; T32 AI007245 United States AI NIAID NIH HHS; UC6 AI058607 United States AI NIAID NIH HHS; T32 GM007753 United States GM NIGMS NIH HHS; U54 CA260543 United States CA NCI NIH HHS; R01 AI146779 United States AI NIAID NIH HHS; T32 GM008313 United States GM NIGMS NIH HHS; U24 GM129539 United States GM NIGMS NIH HHS; U19 AI142596 United States AI NIAID NIH HHS; U42 OD021458 United States OD NIH HHS; P40 OD012217 United States OD NIH HHS; S10 OD018164 United States OD NIH HHS; R01 AI145687 United States AI NIAID NIH HHS |
| فهرسة مساهمة: | Keywords: COVID-19; N-terminal domain; SARS-CoV-2; antibody-dependent enhancement; cross-neutralization; electron micrograph; infection enhancement; in vivo protection; neutralizing antibody; receptor-binding domain |
| المشرفين على المادة: | 0 (Antibodies, Neutralizing) 0 (Antibodies, Viral) 0 (Cytokines) 0 (Receptors, IgG) 0 (Spike Glycoprotein, Coronavirus) 0 (spike protein, SARS-CoV-2) |
| تواريخ الأحداث: | Date Created: 20210709 Date Completed: 20210819 Latest Revision: 20240923 |
| رمز التحديث: | 20240923 |
| مُعرف محوري في PubMed: | PMC8232969 |
| DOI: | 10.1016/j.cell.2021.06.021 |
| PMID: | 34242577 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1097-4172 |
|---|---|
| DOI: | 10.1016/j.cell.2021.06.021 |